COVID-19 vaccine dose numbers by top manufacturer 2021

As of March 9, 2021, there were pre-purchase agreements for over three billion doses of AstraZeneca/Oxford's vaccine. This vaccine is by far the most sought after COVID-19 vaccine, especially due to its ability to be stored at normal refrigerator temperatures, while other vaccines might need ultra cold storage. Although still in phase III of clinical trials and without approval, Novavax's vaccine is the one with the second highest number of orders worldwide. Global COVID-19 vaccine contractsAt the same time, India had managed to secure around 2.2 billion COVID-19 vaccines doses, followed by the European Union which had signed pre-purchase agreements to secure nearly 1.84 billion doses of COVID-19 vaccines, while the United States already secured around 1.21 billion doses. AstraZeneca/Oxford's vaccine accounted for one billion doses of all vaccines secured by India, while also accounting for 300 million doses of all vaccines secured by the EU and the U.S., respectively. Forecasted sales of COVID-19 vaccinesAs of November 2021, Comirnaty by BioNTech/Pfizer was the leading COVID-19 vaccine by forecasted sales revenue. It was expected to make around 36 billion U.S. dollars in sales revenue in 2021, followed by 29 billion dollars in 2022. Meanwhile, Spikevax by Moderna was projected to make 18 billion and 22 billion U.S. dollars in 2021 and 2022, respectively. Vaxzevria by AstraZeneca was forecasted to make 1.7 billion U.S. dollars in sales, followed by an additional 1.9 billion dollars by 2022. In contrast to most other biopharmaceutical companies, AstraZeneca had announced to sell its vaccine at almost net cost price.

截至2021年3月9日，已有超过三十亿剂阿斯利康/牛津大学的疫苗的预购协议。该疫苗无疑是全球最受欢迎的COVID-19疫苗，尤其得益于其能够在常规冷藏温度下储存，而其他疫苗可能需要超低温储存。尽管Novavax的疫苗仍处于III期临床试验阶段且尚未获得批准，但全球订单数量位居第二。在全球COVID-19疫苗合同方面，印度成功确保了约22亿剂COVID-19疫苗，紧随其后的是欧盟，已签订预购协议以确保近18.4亿剂COVID-19疫苗，而美国已确保约12.1亿剂。阿斯利康/牛津大学的疫苗占印度所确保的全部疫苗剂量的十亿剂，同时占欧盟和美国所确保的全部疫苗剂量的三亿剂。关于COVID-19疫苗的预测销售额，截至2021年11月，BioNTech/Pfizer的Comirnaty疫苗预计将成为销售额最高的COVID-19疫苗。预计2021年销售额将达到约360亿美元，2022年将达到290亿美元。与此同时，Moderna的Spikevax疫苗预计2021年和2022年的销售额分别为180亿美元和220亿美元。阿斯利康的Vaxzevria疫苗预计2021年销售额为17亿美元，到2022年将增加至19亿美元。与大多数其他生物制药公司不同，阿斯利康宣布将以几乎净成本价出售其疫苗。